MRI MRCP - Cyst (IPMN) - Newbie
So much gratitude for this group. Thank you !
My New GI doctor at University of Miami Healthcare ordered this test after I called needing colonoscopy. I discussed frequent abdominal pain, bloating, and more frequent bouts of pancreatitis. The findings:
Pancreas: Homogeneous parenchymal enhancement with a 0.6 cm cystic lesion in the pancreatic body, likely reflecting a small side branch IPMN. Otherwise, no lesions or ductal dilatation dilatation.
Should there be further testing of these finding? I have not heard from Dr yet. The test was last week, I obtained results from portal. “Is NO news GOOD news?”
Again, many many thanks.
Chase
Interested in more discussions like this? Go to the Pancreatic Cancer Support Group.
@frances007
Did you know that there is a Hearing Loss group on Connect? See here: https://connect.mayoclinic.org/group/hearing-loss/
Waiting is stressful. I notice in your bio that you are an artist. You may find it helpful to join this discussion:
- Art for Healing https://connect.mayoclinic.org/discussion/art-for-healing/
Fellow members share how art helps them and even share their creations. I hope you'll join in.
I read that the new protocol on BD- IPMNs is no longer saying do nothing if under 3cm but instead says that no matter the size if patient has other symptoms or duct dilation (I can’t remember if it said double duct dilation or just dilated duct) then more should be done. MRIs to follow either every 6 months or yearly or possible more depending on what’s going on.
Would you please provide the source on the new protocol for monitoring BD-IPMNs?
Thanks
I too would be interested in the source of the new recommendations as I would like to read more in depth.
There is a clinical study underway at multiple sites around the USA that is sponsored by ECOG-ACRIN Cancer Group (Eastern Comprehensive Oncology Group-American College of Radiology Imaging Network). The study is EA2185 (https://ecog-acrin.org/clinical-trials/ea2185-pancreas-cancer-prevention/). The purpose is to evaluate two surveillance methods with the objective of which provides better information and a secondary objective of ensuring no patient undergoes an interventional procedure that is unnecessary.
Yes, it’s called the Fukuoka guidelines and was revised in 2017. If the link doesn’t work then just type in internet search: 2022 Fukuoka guidelines IPMNs and you will get many links that should bring you to same. I tried attaching the link but a message came up that since I’m a new member I cannot attach links to my posts. Again, just do an internet search for the following: 2022 Fukuoka Guidelines IPMNs
Fukuoka guidelines for IPMNs in 2017
I wish I could attach some links. I spent a tremendous amount of time researching IPMNs about 8 to 12 months ago and I saved a lot of the links in an email folder. When you asked me to show you where I found the newest guidelines, I came across a lot of really good info that I had forgotten about. ..
Those are existing guidelines since 2017. I’m familiar with those as I have referred to them many times. I thought you mentioned you saw newer guidelines. That’s what I am interested in seeing if they exist. As far as I recall, no newer guidelines exist. The Fukuoka guidelines are the most current issued by that working group.
Here is the link to the 2017 Fukuoka IPMN Management guidelines also available as a pdf file from the same link.
https://www.sciencedirect.com/science/article/pii/S1424390317305161
I will read them again but what I meant was that the older guidelines I thought had said to do nothing about IPMNs if they are less than 3 but the newer 2017 guidelines if I remember correctly are saying that if a person also has dilated ducts and or other concerning symptoms then you do do something regardless of the size of the IPMNs. In some cases that could mean just yearly MRIs to follow and in some cases it might mean surgery.